Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS

Author(s):

Ahmed Zayed Obeidat, MD, PhD,Riley Bove, MD

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

EP: 1.Multiple Sclerosis Disease Course and Classification

EP: 2.Defining the Utility of PIRA in Practice

EP: 3.Addressing Inflammation Upon the Diagnosis of MS

EP: 4.Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches

EP: 5.Shared Decision-Making in Multiple Sclerosis Treatment

EP: 6.Clinical Trial Design and Personalized Medicine in Multiple Sclerosis

EP: 7.Customizing Treatment Approaches With High Efficacy Therapies

EP: 8.When to Stop Multiple Sclerosis Therapy

EP: 9.Immunological Phenotypes of Multiple Sclerosis and Patient Race

EP: 10.Pregnancy and Lactation in Multiple Sclerosis

EP: 11.Bladder Management and Patient-Reported Outcomes in Multiple Sclerosis Management

EP: 12.The Importance of Lifestyle Changes in Multiple Sclerosis Care

EP: 13.Anti-CD20 Therapies for MS

EP: 14.Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies

EP: 15.Safety of Anti-CD20 Therapies in Multiple Sclerosis

EP: 16.Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis

EP: 17.Biomarkers for Dosing Multiple Sclerosis Therapies

Now Viewing

EP: 18.Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS

This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.

The conversation concludes with each participant offering insights and advice regarding the use of NTCD-20 therapies in clinical practice. The speaker emphasizes the importance of reassurance for newly diagnosed patients, highlighting the evolving nature of research and the wealth of data available to inform long-term treatment decisions.

The speaker underscores the positive outcomes observed in patients on NTCD-20 medications but highlights the need for further research, especially regarding older patients and rare complications. She emphasizes the importance of personalized medicine and the need for clarity on treatment duration and discontinuation protocols.

The speaker echoes the sentiment of reassurance for patients and emphasizes the need for vigilance among prescribers, staying updated on emerging literature and monitoring patients for potential complications. She also highlights the need for precision medicine approaches in multiple sclerosis (MS) treatment.

The speaker adds to the discussion by emphasizing the need for long-term studies to assess the impact of NTCD-20 therapies on disease progression, particularly in patients with late-onset MS. She advocates for personalized medicine and the development of biomarkers to guide treatment decisions.

Overall, the conversation highlights the importance of staying informed, reassurance for patients, and the need for precision medicine approaches in MS treatment. The participants express gratitude for the discussion and hope that it proves useful and informative to the audience.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.